Opinion

Video

Logistical and Access Challenges with CAR T-cell Therapy in R/R ALL

Experts in acute lymphoblastic leukemia examine the logistical challenges associated with CAR T-cell therapy delivery and assess the frequency of patient attrition due to manufacturing delays.

Video content above is prompted by the following:

  • What are some logistical barriers with delivery of CAR T-cell Therapy?
  • How frequently do your patients have to drop out from CAR T-cell therapy due to manufacturing time? How does it compare to the rates in the ZUMA-3 and FELIX Study?
  • How feasible is it for your patients to remain in close proximity to the hospital per the REMS requirements?
  • Have you observed any additional or unique access challenges in minority populations?
Related Videos
Hope Rugo, MD, FASCO, and Aditya Bardia, MD, MPH, FASCO
2 KOLs are featured in this series.
2 KOLs are featured in this series.
5 KOLs are featured in this series.
5 KOLs are featured in this series.
A panel of 3 experts on nasopharyngeal carcinoma